CKD 349
Alternative Names: CKD-349Latest Information Update: 28 Dec 2024
At a glance
- Originator Chong Kun Dang
- Class Heart failure therapies; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic heart failure; Renal failure
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Chronic-heart-failure(In volunteers) in South Korea (PO)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Renal-failure in South Korea (PO, Tablet)
- 06 Apr 2022 Chong Kun Dang Pharmaceutical completes a phase I trial in Chronic heart failure (In volunteers) in South Korea (PO) (NCT05089279)